MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MOUNTAINEER
- Sponsors Seattle Genetics
- 22 Nov 2019 Planned number of patients changed from 40 to 110.
- 22 Nov 2019 Planned End Date changed from 30 Jun 2020 to 31 Dec 2021.
- 22 Nov 2019 Planned primary completion date changed from 30 Jun 2020 to 31 Aug 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History